<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02811575</url>
  </required_header>
  <id_info>
    <org_study_id>RC31/16/8217</org_study_id>
    <nct_id>NCT02811575</nct_id>
  </id_info>
  <brief_title>Type 2 Diabetes and Alteration of Immune System of Intestinal Mucosa : Proof of Concept</brief_title>
  <acronym>SIMMUNIDIA</acronym>
  <official_title>Type 2 Diabetes and Alteration of Immune System of Intestinal Mucosa : Proof of Concept</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Type 2 diabetes is the predominant type of diabetes. Because a quiet evolution, it is&#xD;
      difficult to have a rapid diagnose. A better knowledge about pathophysiological mechanisms at&#xD;
      the origin of type 2 diabetes and about its complications could make it possible to improve&#xD;
      the prevention and the treatment of this disease.&#xD;
&#xD;
      Research team developped a new research axis : the microbiota of the intestinal mucosa. They&#xD;
      proved a translocation process of intestinal bacteria from the intestinal mucosa to different&#xD;
      tissue of the organism implicated in glucose homeostasis. This mechanism is involved in the&#xD;
      type 2 diabetes development. A clinical study (MICIMAB) of predictive biomarkers of diabetes&#xD;
      and obesity is ongoing.&#xD;
&#xD;
      In parallel, the same team explored the role of intestinal immunity modifications in the&#xD;
      bacteria translocation from the gut to the blood circulation. They already have some results&#xD;
      on animal model but not yet in human. In animal model, a solid reduction of lymphocytes T CD4&#xD;
      Th17 in the intestinal wall is responsable of the translocation of intestinal bacteria and in&#xD;
      the induction of a metabolic inflammation wich promotes insulin resistance, abdominal obesity&#xD;
      development and type 2 diabetes.&#xD;
&#xD;
      The aim of this study is to explore this hypothesis in human to have therapeutic solution&#xD;
      later.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2016</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of lymphocyte TCD4 Th17 in colon sample</measure>
    <time_frame>Day 1</time_frame>
    <description>After colon biopsy, lymphocytes TCD4 Th17 are counted in biopsy sample.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of lymphocyte TCD4 Th17 in ileon sample</measure>
    <time_frame>Day 1</time_frame>
    <description>After ileon biopsy, lymphocytes TCD4 Th17 are counted in biopsy sample.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of CD45+ cells in colon sample</measure>
    <time_frame>Day 1</time_frame>
    <description>After colon biopsy, CD45+ cells are counted in biopsy sample.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of CD45+ cells in ileon sample</measure>
    <time_frame>Day 1</time_frame>
    <description>After ileon biopsy, CD45+ cells are counted in biopsy sample.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activation of CD45+ cells in colon sample</measure>
    <time_frame>Day 1</time_frame>
    <description>After colon biopsy, CD45+ cells are analysed to see their state of activation in biopsy sample.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activation of CD45+ cells in ileon sample</measure>
    <time_frame>Day 1</time_frame>
    <description>After ileon biopsy, CD45+ cells are analysed to see their state of activation in biopsy sample.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiota sequencing in blood sample</measure>
    <time_frame>Day 1</time_frame>
    <description>Microbiota will be sequencing in blood sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiota quantification in blood sample</measure>
    <time_frame>Day 1</time_frame>
    <description>Microbiota will be quantified in blood sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiota sequencing in ileon sample</measure>
    <time_frame>Day 1</time_frame>
    <description>Microbiota will be sequencing in ileon sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiota sequencing in colon sample</measure>
    <time_frame>Day 1</time_frame>
    <description>Microbiota will be sequencing in colon sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiota quantification in ileon sample</measure>
    <time_frame>Day 1</time_frame>
    <description>Microbiota will be quantified in ileon sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiota quantification in colon sample</measure>
    <time_frame>Day 1</time_frame>
    <description>Microbiota will be quantified in colon sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bacteria production</measure>
    <time_frame>Day 1</time_frame>
    <description>Culture of biological samples to study the bacteria production</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">135</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Patients with diabetes</arm_group_label>
    <description>Patients with type 2 diabetes will have biopsy during coloscopy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Patients without type 2 diabetes will have biopsy during coloscopy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biopsy</intervention_name>
    <description>Ileon and colon biopsy</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Patients with diabetes</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Ileon and colon biopsy&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a diagnoses of type 2 diabetes and patient who do not have a know diabetes&#xD;
        diagnose.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Coloscopy indication&#xD;
&#xD;
          -  Capacity to give a written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type 1 diabetes&#xD;
&#xD;
          -  Severe renal failure&#xD;
&#xD;
          -  Antecedent of liver fibrosis and/or liver failure&#xD;
&#xD;
          -  Antecedent of inflammatory bowel disease, lymphocyte colitis, celiac disease or colon&#xD;
             cancer&#xD;
&#xD;
          -  Antecedent of obesity surgery or of total colectomy&#xD;
&#xD;
          -  Antecedent of documented intestinal ischaemia&#xD;
&#xD;
          -  Acute infection the week before the inclusion&#xD;
&#xD;
          -  Congenital of acquired immune deficiency&#xD;
&#xD;
          -  Chronic viral infection&#xD;
&#xD;
          -  Antibiotic of probiotic the month before the coloscopy&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Patients participating to another research with an exclusion period&#xD;
&#xD;
          -  Patients under guardianship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Gourdy</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pierre Gourdy</last_name>
    <email>gourdy.p@chu-toulouse.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Gourdy</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>June 21, 2016</study_first_submitted>
  <study_first_submitted_qc>June 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2016</study_first_posted>
  <last_update_submitted>November 6, 2020</last_update_submitted>
  <last_update_submitted_qc>November 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coloscopy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

